References

Chapter 1

2 References


References

Chapter 2


4 References


References

Chapter 3


References


42 Widdifield J, Bernatsky S, Paterson J, et al. Accuracy of Canadian health administrative databases in identifying patients with rheumatoid arthritis: a validation study using the medical records of


68 Uijen AA, Heinst CW, Schellevis FG, van den Bosch WJ, van de Laar FA, Terwee CB, Schers HJ. Measurement properties of questionnaires measuring
References


References

Chapter 4


17 The American Health Information Management Association website: www.ahima.org.


Published 2016 by John Wiley & Sons, Ltd.
2 References


23 Blaya JA, Fraser HS, Holt B. E-health technologies show promise in developing countries. Health Affairs (Project Hope). 2010;29(2):244–51.


43 Smith MW, Joseph GJ. Pharmacy data in the VA health care system. Medical Care Research and Review. 2003;60(3 Suppl.):925–1235.


58 IMS Hospital Treatment Insights website: www.imshealth.com.


61 Ruiter R, Visser LE, van Herk-Sukel MP, Geelhoed-Duijvestijn PH, de Bie S, Straus SM, et


102 Balkrishnan R, Bhosle MJ, Camacho F, Fleischer AB, Feldman SR. Prescribing patterns for topical retinoids: analyses of 15 years of data from the


References

Chapter 5

4 WHO Collaborating Centre for Drug Statistics Methodology for the ATC/DDD Methodology website: www.whocc.no.
12 WHO Collaborating Centre for Drug Statistics Methodology for the ATCvet Classification website: www.whocc.no/atcvet.
15 EphMRA Anatomical Classification website: www.ephmra.org/Anatomical-Classification.
20 Prescribing Data (Presentation Level) by GP Practice: Glossary of Terms. Leeds, Health and Social
2 References


References

Chapter 6

2 WHO Collaborating Centre website: www.who.cc
18 Bronzwaer SL, Cars O, Buchholz U, Mölstad S, Gottsch W, Veldhuijzen IK, et al.; European Anti-


37. Plet HT, Hallas J, Kjeldsen LJ. Adherence to hospital drug formularies and cost of drugs in hospitals in
References
References

Chapter 7

2 WHO Collaborating Centre for Drug Statistics Methodology website: www.whocc.no.


References

Chapter 8


5. van Mossevelde C. EUROSTAT’s activities in the area of health system comparisons. European Journal of Public Health. 2007;66–.


19. Vogler S. How large are the differences between originator and generic prices? Analysis of five molecules
2 References


22 PHIS database: https://phis.goeg.at/index.aspx?_nav0029.


References


45 European Pharmaceutical Marketing Research Association (EphMRA), EphMRA Lexicon: A Pocket Guide to Pharmaceutical Marketing and Marketing Research Terms and Definitions.


49 Danzon PM, Furukawa MF. Prices and availability of pharmaceuticals: evidence from nine countries. Health Affairs. 2003;W3-521.


References

Chapter 9

8 Kalinowski P. Understanding confidence intervals (CIs) and effect size estimation. Observer. 2010:23.
References

Chapter 10

24 BoxPlotR: boxplot.tylerlab.com.
References


39 Google Drive with Motion Chart: www.gapminder.org.

40 Gapminder World: www.gapminder.org/world.

41 OECD data lab: http://www.oecd.org/statistics/datalab/


50 Orange: orange.biolab.si.

References

Chapter 11


15 Ohlsson H, Librero J, Sundquist J, Sundquist K, Merlo J. Performance evaluations and league tables: do they capture variation between organizational units? An analysis of 5 Swedish phar-


References


88 Dreischulte T, Grant AM, McCowan C, McNaw JJ, Guthrie B. Quality and safety of medication use in primary care: consensus validation of a new set of


108 Chassin MR, Loeb JM, Schmaltz SP, Wachter RM. Accountability measures – using measurement to


References

Chapter 13

2 References


References

Chapter 14

16 The Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium (PROTECT) (last accessed 20 December 2015).
References


4 References


References

Chapter 15


3 Pharmaceutical Health Information System. PHIS Hospital Pharma Report. Austria. 2010.


References


References

Chapter 16


16 Bunting BA, Cranor CW. The Asheville Project: long-term clinical, humanistic, and economic out-
32 Chimonas MA, Gessner BD. Airborne particulate matter from primarily geologic, non-industrial sources at levels below National Ambient Air Quality Standards is associated with outpatient visits for asthma and quick-relief medication prescriptions among children less than 20 years old enrolled in Medicaid in Anchorage, Alaska. *Environmental Research*. 2007;103(3):397–404.
References

Chapter 17


2 References


34 Schwartz JB. The current state of knowledge on age, sex, and their interactions on clinical pharmacology. *Clinical Pharmacology and Therapeutics.* 2007;82(1):87–96.


38 Gu Q, Burt VL, Paulose-Ram R, Dillon CF. Gender differences in hypertension treatment, drug utilization patterns, and blood pressure control among US adults with hypertension: data from the National Health


59 Nielsen MW, Hansen EH, Rasmussen NK. Patterns of psychotropic medicine use and related diseases across educational groups: national cross-sectional


Chapter 18


18 Wettermark B, Jacobsson B, Godman B, Haaijer-Ruskamp F. Soft regulations in pharmaceutical...


40 Putrik P, Ramiro S, Kvien TK, Sokka T, Pavlova M, Uhlig T, Boonen A; Working Group ‘Equity


61 Filion KB, Delaney JA, Brophy JM, Ernst P, Suisse S. The impact of over-the-counter simvastatin on the


References

Chapter 19

Key references/suggested reading are marked with an asterisk. *


27 Vogler S. The impact of pharmaceutical pricing and reimbursement policies on generics uptake: implementa-
pdf/16379320.pdf (last accessed 18 November 2015). *Good overview of managed entry strategies across Europe – their strengths as well as concerns.


References


References

Chapter 20

Key references/suggested reading are marked with an asterisk.*


2 References


References


78 European Medicines Agency. CHMP Recommendations for the Pharmacovigilance Plan as Part of


References

Chapter 21

Key references/suggested reading are marked with an asterisk.*


Published 2016 by John Wiley & Sons, Ltd.


4 References


References


References

Chapter 22


References


References


References

Chapter 23

2 References


38 Bakker MK, Kolling P, van den Berg PB, de Walle HE, de Jong van den Berg LT. Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort


References


70 EUROMediCAT website: www.euromedicat.eu.


72 Eysenbach G. Improving the quality of Web surveys: the Checklist for Reporting Results of Internet E-Surveys (CHERRIES). *Journal of Medical Internet Research.* 2004;6(3):e34.


References

Chapter 24


References


38 Shankar PR, Upadhyay DK, Subish P, Dubey AK, Mishra P. Prescribing patterns among pediatric


References

Chapter 25


References


39 Harugeri A, Joseph J, Parthasarathi G, Ramesh M, Guido S. Prescribing patterns and predictors of


References


81 Fox C, Richardson K, Maidment ID, Savva GM, Matthews FE, Smithard D, et al. Anticholinergic medication use and cognitive impairment in the


References

References

Chapter 26


12 Shaban RZ, Cruickshank M, Christiansen K; The Antimicrobial Resistance Standing Committee. National surveillance and reporting of antimicrobial resistance and antibiotic usage for human health in Australia. Available from:
References


47 Mainous AG 3rd, Cheng AY, Garr RC, Tilley BC, Everett CJ, McKee MD. Nonprescribed antimicrobial
4 References


65 Blix HS, England A, Liteskare I, Ronning M. Age- and gender-specific antibacterial prescribing
 REFERENCES


References


Hanberger H, Arman D, Gill H, Jindrak V, Kalenic S, Kurcz A, et al. Surveillance of microbial resistance in European Intensive Care Units: a first report from the Care-ICU programme for...


References

Chapter 27


References


92 Reeve E, Shakib S, Hendrix I, Roberts MS, Wiese MD. Review of deprescribing processes and development of an evidence based, patient-centred
References


References

Chapter 28


19 Barozzi N, Tett SE. Perceived barriers to paracetamol (acetaminophen) prescribing, especially follow-


58 Gustafsson M, Karlsson S, Lovheim H. Inappropriate long-term use of antipsychotic drugs is common among people with dementia living in specialized care units. *BMCMedical andPharmacology and Toxicology*. 2013;14:10.


64 Siriwardena AN, Qureshi MZ, Dyas JV, Middleton H, Orner R. Magic bullets for insomnia? Patients’ use and experiences of newer (Z drugs) versus older


95 Mojtabai R, Olsson M. Proportion of antidepressants prescribed without a psychiatric diagnosis is growing. Health Affairs. 2011;30:1434–42.


References

Chapter 29


2 References


References

77 Papp KA, Strober B, Augustin M, Calabro S, Lomdh A, Chevrier M. PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. Journal of Drugs in Dermatology. 2012;11(10):1210–17.
References


Chapter 30


39 Cheema PK, Gavura S, Migos M, Godman B, Yeung L, Trudeau ME. International variability in the reimbursement of cancer drugs by pub-


59 Lee SJ, Earle CC, Weeks JC. Outcomes research in oncology: history, conceptual framework, and


References

Chapter 31


References


References

Chapter 32


16 Figueras A. The use of drugs is not as rational as we believe... but it can’t be! The emotional roots of prescribing. European Journal of Clinical Pharmacology. 2011;67:433–5.


51 NPS Medicinewise website: www.nps.org.au.


4 References


Chapter 33


21 Moen AC, Bohma A, Tilenius T, Antonov B, Nilsson JLG, Ring L. ‘I don’t know how many of these [medicines] are necessary’: a locus group study


4 References


References

Chapter 34


References

References

Chapter 35


4 Blaschke TF, Osterberg L, Vrijens B, Urquhart J. Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annual Review of Pharmacology and Toxicology. 2012;52:275–.


15 Garfield S, Clifford S, Eliasson L, Barber N, Willson A. Suitability of measures of self-reported medication adherence for routine clinical use: a sys-
tematic review. BMC Medical Research Methodology. 2011;11:149.


References

Chapter 36


References

Chapter 37


2 References


58 Roberts AS, Benrimoj SI, Chen TF, Williams KA, Aslani P. Implementing cognitive services in community pharmacy: a review of facilitators used in...
4 References


References

Chapter 38


guideline_rev2_en.pdf (last accessed 18 November 2015).
References

Chapter 39

References

References

Chapter 40


Chapter 41

38 Schneider EC, Zaslavsky AM, Landon BE, Lied TR, Sheingold S, Cleary PD. National quality monitoring of Medicare health plans: the relationship between


42 Black N, Varaganum M, Hutchings A. Relationship between patient reported experience (PREMs) and patient reported outcomes (PROMs) in elective surgery. British Medical Journal Quality & Safety. 2014;23:534–42.

References

Chapter 42


References


Chapter 43


56 World Health Organization. How to Investigate Drug Use in Health Facilities: Selected Drug Use Indicators – EDM Research Series No. 007. Available from:
4 References


References

Chapter 44


16 Cheung KC, vandenBemt PM, Bouvy ML, Wensing M, De Smet PA. Medication incidents related to automated dose dispensing in community pharmacies.
2 References


References


62 Van Wijk B, Klugel O, Heerdink E, de Boer A. Effectiveness of interventions by community pharmacists to improve patient adherence to chronic medi-


65 Graaabe T, Kjeldsen LJ. Medication reviews by clinical pharmacists at hospitals lead to improved patient outcomes: a systematic review. *Basic & Clinical Pharmacology & Toxicology*. 2013;112:359–73.


82 Curtiss FR, Fry RN, Avey SG. Framework for pharmacy services quality improvement – a bridge to cross the quality chasm. Part I. The opportunity
105 Robertson HA, MacKinnon NJ. Development of a list of consensus-approved clinical indicators
 References


124 IGZ Health Care Inspectorate. KNMP Royal Dutch Association for the Advancement of Pharmacy. Quality Indicators for Pharmacies. Utrecht, September 2009.


References

Chapter 45


17 Bloom BS. Effects of continuing medical education on improving physician clinical care and patient...
References


31 Cochrane Effective Practice and Organisation of Care Group. EPOC-specific resources for review authors. Available from: http://epoc.cochrane.org/epoc-specific-resources-review-authors (last accessed 18 November 2015).


41 Canadian Agency for Drugs and Technology in Health. Rx for Change Interventions Database. Available from: https://www.cadth.ca/rx-change (last accessed 18 November 2015).


58 Shea S, DuMouchel W, Bahamonde L. A meta-analysis of 16 randomized controlled trials to evaluate computer-based clinical reminder systems for preventive care in the ambulatory setting. *Jour-


References

Chapter 46


20 Green LW, Kreuter MW. CDC’s planned approach to community health as an application of PRECEDE


References

Chapter 47

19 Dismuke CE, Egede LE. Medicare part D prescription drug program: benefits, unintended conse-
References


